Skip to main content
Top

08-05-2017 | Neonatal diabetes | Article

Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement

Journal: Diabetologia

Authors: Timothy J. McDonald, Rachel E. Besser, Mandy Perry, Tarig Babiker, Bridget A. Knight, Maggie H. Shepherd, Sian Ellard, Sarah E. Flanagan, Andrew T. Hattersley

Publisher: Springer Berlin Heidelberg

Abstract

Aims/hypothesis

The majority of infants with neonatal diabetes mellitus present with severe ketoacidosis at a median of 6 weeks. The treatment is very challenging and can result in severe neurological sequelae or death. The genetic defects that cause neonatal diabetes are present from birth. We aimed to assess if neonatal diabetes could be diagnosed earlier by measuring glucose in a dried blood spot collected on day 5 of life.

Methods

In this retrospective case–control study we retrieved blood spot cards from 11 infants with genetically confirmed neonatal diabetes (median age of diagnosis 6 [range 2–112] days). For each case we also obtained one (n = 5) or two (n = 6) control blood spot cards collected on the same day. Glucose was measured on case and control blood spot cards. We established a normal range for random glucose at day 5 of life in 687 non-diabetic neonates.

Results

All 11 neonates with diabetes had hyperglycaemia present on day 5 of life, with blood glucose levels ranging from 10.2 mmol/l to >30 mmol/l (normal range 3.2–6.0 mmol/l). In six of these neonates the diagnosis of diabetes was made after screening at day 5, with the latest diagnosis made at 16 weeks.

Conclusions/interpretation

Neonatal diabetes can be detected on day 5 of life, preceding conventional diagnosis in most cases. Earlier diagnosis by systematic screening could lead to prompt genetic diagnosis and targeted treatment, thereby avoiding the most severe sequelae of hyperglycaemia in neonates.
Literature
1.
Slingerland AS, Shields BM, Flanagan SE et al (2009) Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 52:1683–1685CrossRefPubMedPubMedCentral
2.
Wiedemann B, Schober E, Waldhoer T et al (2010) Incidence of neonatal diabetes in Austria-calculation based on the Austrian diabetes register. Pediatr Diabetes 11:18–23CrossRefPubMed
3.
Iafusco D, Massa O, Pasquino B et al (2012) Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol 49:405–408CrossRefPubMed
4.
De Franco E, Flanagan SE, Houghton JA et al (2015) The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 386:957–963CrossRefPubMedPubMedCentral
5.
Stoy J, Edghill EL, Flanagan SE et al (2007) Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 104:15040–15044CrossRefPubMedPubMedCentral
6.
Babenko AP, Polak M, Cave H et al (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456–466CrossRefPubMed
7.
Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849CrossRefPubMed
8.
Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477CrossRefPubMed
9.
Gloyn AL, Diatloff-Zito C, Edghill EL et al (2006) KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Genet 14:824–830CrossRefPubMed
10.
Busiah K, Verkarre V, Cave H, Scharfmann R, Polak M (2014) Human pancreas endocrine cell populations and activating ABCC8 mutations. Horm Res Paediatr 82:59–64CrossRefPubMed
11.
Jose B, Griffiths U, Barrett T, Hattersley AT, Milles JJ (2009) Glibenclamide controls ketosis-prone diabetes in a 38-year-old woman with Kir6.2 mutation. Pract Diabetes Int 26:244–245CrossRef
12.
Day JO, Flanagan SE, Shepherd MH et al (2017) Hyperglycaemia-related complications at the time of diagnosis can cause permanent neurological disability in children with neonatal diabetes. Diabet Med 34:1000–1004CrossRefPubMedPubMedCentral
13.
Hattersley AT, Ashcroft FM (2005) Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54:2503–2513CrossRefPubMed
14.
Therrell BL, Padilla CD, Loeber JG et al (2015) Current status of newborn screening worldwide: 2015. Semin Perinatol 39:171–187CrossRefPubMed
15.
Public Health England (2012). Newborn blood spot screening programme. Available from http://​www.​gov.​uk/​government/​collections/​newborn-blood-spot-screening-programme-supporting-publications. Accessed July 2017
16.
Knight B, Shields BM, Hattersley AT (2006) The Exeter family study of childhood health (EFSOCH): study protocol and methodology. Paediatr Perinat Epidemiol 20:172–179CrossRefPubMed
17.
Shields BM, Knight B, Shakespeare L et al (2006) Determinants of insulin concentrations in healthy 1-week-old babies in the community: applications of a bloodspot assay. Early Hum Dev 82:143–148CrossRefPubMed
18.
Wilson JM, Jungner YG (1968) Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65:281–393PubMed
19.
Public Health England (2013) Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. Available from http://​www.​gov.​uk/​government/​publications/​evidence-review-criteria-national-screening-programmes/​criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme. Accessed July 2017
20.
Busiah K, Drunat S, Vaivre-Douret L et al (2013) Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected]. Lancet Diabetes Endocrinol 1:199–207CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »